MA54521A - Dérivés d'oxopyridine substitués - Google Patents
Dérivés d'oxopyridine substituésInfo
- Publication number
- MA54521A MA54521A MA054521A MA54521A MA54521A MA 54521 A MA54521 A MA 54521A MA 054521 A MA054521 A MA 054521A MA 54521 A MA54521 A MA 54521A MA 54521 A MA54521 A MA 54521A
- Authority
- MA
- Morocco
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- oxopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54521A true MA54521A (fr) | 2022-03-30 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054521A MA54521A (fr) | 2018-12-21 | 2019-12-18 | Dérivés d'oxopyridine substitués |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (fr) |
| JP (1) | JP2022514303A (fr) |
| KR (1) | KR20210106504A (fr) |
| CN (1) | CN113474348A (fr) |
| AR (1) | AR117435A1 (fr) |
| AU (1) | AU2019407909B2 (fr) |
| BR (1) | BR112021009435A2 (fr) |
| CA (1) | CA3124220A1 (fr) |
| CL (1) | CL2021001613A1 (fr) |
| CO (1) | CO2021007908A2 (fr) |
| CR (1) | CR20210342A (fr) |
| DO (1) | DOP2021000128A (fr) |
| EA (1) | EA202191764A1 (fr) |
| EC (1) | ECSP21043895A (fr) |
| IL (1) | IL283990A (fr) |
| JO (1) | JOP20210161A1 (fr) |
| MA (1) | MA54521A (fr) |
| MX (1) | MX2021007508A (fr) |
| PE (1) | PE20211790A1 (fr) |
| SG (1) | SG11202104384PA (fr) |
| TW (1) | TW202039510A (fr) |
| WO (1) | WO2020127504A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093733A1 (fr) * | 2018-03-15 | 2019-09-19 | Bayer Aktiengesellschaft | Procede de preparation de deux derives de 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| US20240174633A1 (en) | 2021-03-09 | 2024-05-30 | Bayer Aktiengesellschaft | Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| JP2024508970A (ja) | 2021-03-09 | 2024-02-28 | バイエル・アクチエンゲゼルシヤフト | （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含んでいる医薬剤形 |
| WO2022189280A1 (fr) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| EP2091947A2 (fr) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Activateurs de glucokinase |
| EP2978425B1 (fr) | 2013-03-27 | 2017-09-27 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| WO2015011087A1 (fr) | 2013-07-23 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Dérivés de l'oxopyridine substitués et utilisation desdits dérivés comme facteur xia/plasma |
| CA2928867A1 (fr) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Derives d'oxopyridine substituee |
| US20170298052A1 (en) | 2014-09-24 | 2017-10-19 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| US10071995B2 (en) | 2014-09-24 | 2018-09-11 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| WO2016046158A1 (fr) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| WO2016046157A1 (fr) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés de pyridobenzazépine et de pyridobenzazocine inhibant le facteur xia |
| US10414731B2 (en) | 2014-09-24 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2722425T3 (es) | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas |
| EP3271332A1 (fr) * | 2015-03-19 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| US20180250280A1 (en) | 2015-09-04 | 2018-09-06 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
-
2019
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/fr active Pending
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/fr unknown
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/fr active Pending
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021007508A (es) | 2021-08-05 |
| EP3898633A1 (fr) | 2021-10-27 |
| SG11202104384PA (en) | 2021-05-28 |
| TW202039510A (zh) | 2020-11-01 |
| JP2022514303A (ja) | 2022-02-10 |
| WO2020127504A1 (fr) | 2020-06-25 |
| CN113474348A (zh) | 2021-10-01 |
| AU2019407909B2 (en) | 2023-05-25 |
| CR20210342A (es) | 2021-08-09 |
| JOP20210161A1 (ar) | 2023-01-30 |
| AU2019407909A1 (en) | 2021-05-27 |
| BR112021009435A2 (pt) | 2021-08-17 |
| EA202191764A1 (ru) | 2021-10-22 |
| AR117435A1 (es) | 2021-08-04 |
| DOP2021000128A (es) | 2021-09-30 |
| CL2021001613A1 (es) | 2021-12-03 |
| KR20210106504A (ko) | 2021-08-30 |
| CO2021007908A2 (es) | 2021-07-19 |
| CA3124220A1 (fr) | 2020-06-25 |
| ECSP21043895A (es) | 2021-07-30 |
| PE20211790A1 (es) | 2021-09-09 |
| IL283990A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA52421A (fr) | Composés pharmaceutiques | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA52948A (fr) | Composés | |
| MA51669A (fr) | Composés | |
| DK3794042T3 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| MA49127A (fr) | Dérivés d'indole n-substitués | |
| MA53003A (fr) | Composés | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| DK3870578T3 (da) | Terapeutiske forbindelser | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
| MA49704A (fr) | Dérivés d'acide biliaire à marquage isotopique | |
| MA52946A (fr) | Composés | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| MA52934A (fr) | Composés inhibiteurs de l'oga | |
| MA52936A (fr) | Composés inhibiteurs d'oga | |
| MA52937A (fr) | Composés inhibiteurs d'oga | |
| MA56504A (fr) | Dérivés de pyridin-3-yle |